Plain-English translation of NCT07216391 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes Mellitus research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two different medications— and —can help slow down type 1 diabetes in people who have early signs of the disease but haven't yet developed full diabetes. Researchers will compare how well each medication works at delaying diabetes progression over time. The study will enroll 60 people between ages 4 and 34 who have stage 2 type 1 diabetes.
Type 1 diabetes develops in stages, and if caught early, there may be a window of opportunity to slow or delay its progression before symptoms become severe. This trial is designed to test whether these medications can help preserve the body's remaining insulin-producing cells and buy more time before the disease fully develops.
You likely qualify if…
You likely don't qualify if…
You will receive either a 2-dose treatment infusion over 2–3 days or 14 daily infusions over 2 weeks, depending on which group you're assigned to. After the initial treatment, you'll have regular blood tests and glucose tolerance tests at 3, 6, and 12 months in the first year, then every 6 months for follow-up. The entire study may last 3–4 years (possibly longer), with a possibility of extended follow-up visits over about 9 years if the study is extended.
AI-generated summary from trial data · Sep 17, 2026 · Not medical advice
United States